Select your country

North & South America

North & South America

Canada
EN | FR
Colombia

Local distributor

Colombia

Sistemas Medicos, LTDA.

Apartado Aereo 24456
Calle 58 No. 35A61
Bogota
(Colombia)

ph. +571-221-9837
Fax +571-222-5310
Perù

Local distributor

Perù

REIMED, SCRL

Pasaje Villaran 192-194 U-12
Urb. Los Sauces Surquillo
Lima 15076
(Peru)

ph. 511-448-1087
Fax 511-448-3447
Uruguay

Local distributor

Uruguay

Lifenir S.A.

Justicia 2069
C 11800 Montevideo
(Uruguay)

ph. +5982-400-3020
Fax +5982-4007320
Venezuela

Local distributor

Venezuela

SUFOMECA

Torre Polar Oeste
Plaza Venezuela
Floor 7, Room 7C
Caracas
PO Box 1050
(Venezuela)

ph. +582-12-793-3222
Fax +582-12-781-1923

Europe

Europa

Albania

Local distributor

Albania

RX PHARMA Sh.P.K.

Rr Komuna e Parisit
Pallatet Kike - Kulla 2
Tirana
(Albania)

ph. +355 42251091
Bosnia-Herzegowina

Local distributor

Bosnia-Herzegowina

MARK Srl

Via S. Michele 334
34170 Gorizia
(Italy)

ph. +39 481217111
Fax +39 48120719
Bulgaria

Local distributor

Bulgaria

EWOPHARMA AG

73 Persenk Street
App. 27 - Floor 8
1164 Sofia
(Bulgaria)

ph. +359 29624478
Fax +359 28683968
Croatia

Local distributor

Croatia

MARK Srl

Via S. Michele 334
34170 Gorizia
(Italy)

ph. +39 481217111
Fax +39 48120719
Greece

Local distributor

Greece

LERIVA IMAGING S.A.

33 Pigis Avenue &
6 Anapiron Polemou Street
151 27 Melissia
Athens
(Greece)

ph. +30 210-6199886
Fax +30 210 61 78 733
Kosovo

Local distributor

Kosovo

RX PHARMA Sh.P.K.

Rr Komuna e Parisit
Pallatet Kike - Kulla 2
Tirana
(Albania)

ph. +355 42251091
Montenegro

Local distributor

Montenegro

MARK Srl

Via S. Michele 334
34170 Gorizia
(Italy)

ph. +39 481217111
Fax +39 48120719
Romania

Local distributor

Romania

EWOPHARMA A.G. ROMANIA

B-dul Primaverii 19 -21
Sc. B - Et.1 - Sect. 1
011972 - Bucharest
(Romania)

ph. +40 212601344
Fax +40 212029327
Serbia

Local distributor

Serbia

MARK Srl

Via S. Michele 334
34170 Gorizia
(Italy)

ph. +39 481217111
Fax +39 48120719
Slovenia

Local distributor

Slovenia

MARK Srl

Via S. Michele 334
34170 Gorizia
(Italy)

ph. +39 481217111
Fax +39 48120719
Hungary

Local distributor

Ungheria

EWOPHARMA REPRESENTATION OFFICE

Budakeszi ut 73/F
H-1021 Budapest
(Hungary)

ph. +36 12004650
Fax +36 13980316

Eastern Europe, Middle East & Africa

Eastern Europe, Middle East & Africa

Ethiopia

Local distributor

Ethiopia

Caroga Pharma PVT. Ltd

P.O.Box 12627
Addis Abeba

(Ethiopia)

ph. +251 11 4654944 / 11 4161090
Fax +251 11 4654595
Ghana

Local distributor

Ghana

Cyndex Pharmacy

P.O.Box DS 1165 Dansoman
Accra
(Ghana)

ph. +233 21553370
Fax +233-244366622 / 21850072
Israel

Local distributor

Israel

DEXCEL

Or-Akiva 30600
30600000 Israel
(Israel)

ph. +972-4-6364015
Fax +972-4-6364004
Jordan

Local distributor

Jordan

THE ARAB DRUG STORE

Khaleel Al Salem street
Amman
(Jordan)

ph. +962 6 5502995
Fax +962 6 5502984
Kenya

Local distributor

Kenya

Nairobi X-Rays Supplies Ltd.

P.O. Box 41669
Nairobi
(Kenya)

ph. +254 20446265-6-7-8
Fax +254 20 4448515/17
Lebanon

Local distributor

Lebanon

Unione Pharmaceutic. d'Orient

Rue du Musée Imm. Stephan QtrBadaro
Beyrouth
(Lebanon)

ph. +961 1 396085-6
Fax +961 1 396047
Mauritius

Local distributor

Mauritius

The Mauritius Pharmacy

4, Louis Pasteur Str Forest Side
(Mauritius)

ph. +230 6762435
Fax +230 675 1387
Saudi Arabia

Local distributor

Saudi Arabia

SARABEEL COMMERCIAL EST.

Medical Division
P.O. BOX 14795
21434 Jeddah
(Saudi Arabia)

ph. +966 12657 2246

Yousef Ahmed Algosaibi Trading Est.

Seventh Floor Sesmo Building
Dhahran Street
(PO Box 5540)
31432 Dammam
(Saudi Arabia)

ph. +966 382 69 490
Fax +966 382 72 528
South Africa

Local distributor

South Africa

AXIM - Head Office Midrand

121 Gazelle Avenue
Corporate Park South
Midrand Johannesburg 2000
(South Africa)

ph. +27 113140140
Fax +27 113140141
Uganda

Local distributor

Uganda

Kampala X-Rays Suppliers

Plot 181 Bombo Rd (KuBbiri)
P.O. Box 9519
Kampala
(Uganda)

ph. +256 41 534313
Fax +256 41 349919
Ukraine

Local distributor

Ukraine

DELTA MEDlCAL

43 Chernovola
Vishnevoe - 08132
(Ukraine)

ph. +38 445933355

Asia Pacific

Asia Pacific

Australia

Local distributor

Australia

REGIONAL HEALTH CARE GROUP

3-11 Primrose Avenue Rosebery
NSW 2018 - Sydney
(Australia)

ph. +61 296624144
Fax +61 296626040
India

Local distributor

India

Imaging Products (India ) Ltd

Mumbai
(India)

ph. +91 9819725471
Fax +91 2228320208
Indonesia

Local distributor

Indonesia

PT DIPA PHARMALAB INTERSAINS

Jl. Panjang No. 10
Kebon Jeruk
Jakarta 11530
(Indonesia)

ph.  +62 215348644
Fax +62 2153676066
New Zealand

Local distributor

New Zealand

REGIONAL HEALTH LIMITED

19C Orbit Drive
Mairangi Bay
(New Zealand)

ph. +64 94140040
Fax +64 94140041
Pakistan

Local distributor

Pakistan

S. EJAZUDDIN & CO LTD

PO Box 5629 - Zia Plaza
Altaf Hussain Road
74000 Karachi
(Pakistan)

ph. +92 21212032
Fax +92 212629716
Philippines

Local distributor

Philippines

NEW MARKETLINK INTERNATIONAL CORP

Tao Corporate Centre 2291
Don Chino Roches Ave
Ext Makati City Metro
Manila
(Philippines)

ph. (632) 836-5838
Singapore

Local distributor

Singapore

LF ASIA PHARMACEUTICAL DIVISION

Healthcare Distribution Centre
24 Penjuru Road (off Penjuru Close)
#03-04 CWT Commodity Hub
(Singapore 609128)

ph. +65 65097629
Taiwan

Local distributor

Taiwan

SUPER FORTUNE ENTERPRISE CO LTD

5 F-1 - 42 Sec.1 Ming
Sheng E. Road Jehovah Building
101 Taipei
(Taiwan)

ph. +886 225673456
Fax +886 225319231
Thailand

Local distributor

Thailand

Interpharmacare Co., Ltd.

90 Moo 13 Soi Mahacha
Bangpleeyai
Bangplee
Samutprakarn 10540
(Thailand)

ph. + 66 2 675 9140-2
Fax + 66 2 325 0265
Vietnam

Local distributor

Vietnam

HOANG GIA INVESCO, JSC

No 74-76 Hoa Bang Str
Cau Giay
Dist Ha Noi Hanoi
(Viet Nam)

ph. +43 7846952

Magnetic Resonance Imaging

      

Selecting the right contrast is critical.
That’s why Bracco offers two gadolinium-based contrast agents (GBCA) for MRI of the CNS in adult and pediatric patients, and MultiHance for MR angiography (MRA) to evaluate adults with known or suspected renal or aorto-ilio-femoral occlusive vascular disease, letting you choose the right product for each patient.

MultiHance is the MR contrast agent with the highest relaxivity among those approved for use in MRI of CNS lesions and the first extracellular approved for MRA in adults in the U.S.. Or select ProHance®, the first macrocyclic GBCA that provides high kinetic and conditional stability.6,7  With a combined 31 million doses administered worldwide, Bracco delivers proven solutions that allow you to choose the right product for every patient.8

Learn More about the TRUTH Study1
Link to abstract: http://www.ncbi.nlm.nih.gov/pubmed/25300984

Reference 1. Maravilla KR, Smith MP, Vymazal J, Goyal M, Herman M, Baima JJ, Babbel R, Vaneckova M, Zižka J, Colosimo C, Urbańczyk-Zawadzka M, Mechl M, Bag AK, Bastianello S, Bueltmann E, Hirai T, Frattini T, Kirchin MA, Pirovano G. Are There Differences between Macrocyclic Gadolinium Contrast Agents for Brain Tumor Imaging? Results of a Multicenter Intraindividual Crossover Comparison of Gadobutrol with Gadoteridol (the TRUTH Study). AJNR Am J Neuroradiol. 2014 Oct 9. [Epub ahead of print]

 

 

REFERENCES: 1. MultiHance (gadobenate dimeglumine) injection, 529 mg/mL full Prescribing Information. Princeton, NJ: Bracco Diagnostics Inc. July 2012. 2 Bleicher AG, Kanal E. A serial dilution study of gadolinium-based MR imaging contrast agents. AJNR. 2008;29:668-73. 3. Pintaske J, et al. Relaxivity of gadopentetate dimeglumine (Magnevist), gadobutrol (Gadovist), and gadobenate dimeglumine (MultiHance) in human blood plasma at 0.2, 1.5 and 3 Tesla.Erratum Invest. Radiol. 2006;41:213-221 4. Rohrer M, et al. Comparison of magnetic properties of MRI contrast media solutions at different magnetic field strengths. Invest. Radiol. 2005;40:715-724. 5. Kirchin MA, et al. Gadobenate dimeglumine (Gd-BOPTA). An overview. Invest. Radiol. 1998;33(11):798-809. 6. Idee JM, Port C, Raynal I, et al. Clinical and biological consequences of transmetallation induced by contrast agents for magnetic resonance imaging: a review. Fundamental and Clinical Pharmacology. 2006; 20:563-576. 7. ProHance (gadoteridol) injection 279.3 mg/mL full Prescribing Information. Princeton, NJ: Bracco Diagnostics Inc.; Sept 2011. 8. Postmarketing Surveillance and Utilization Report 2010. On file, Bracco Diagnostics Inc.

All trademarks and registration trademarks are the property of the respective owners.

MULTIHANCE highest Relaxivity

MultiHance:
The Highest Relaxivity
Agent for CNS MRI.

Read more

PROHANCE HIGH STABILITY

By all measures,
ProHance is an
exceptionally stable
Gd chelate.
Learn more!

Read more

Acist

ACIST® Medical
Systems is a market
leader in advanced
contrast imaging
systems for
cardiovascular
angiography.

Visit the site

Find Your Rep

Enter your ZIP code in the box below:

logoThe first and only contrast agent indicated for both MRI of the CNS (>2 years) and MRA (adults) in the U.S.
The first macrocyclic gadolinium MRI contrast agent approved in the U.S. for CNS MRI.
EmpowerMr logoEmpowerMR® Contrast Injection System. World's first hydraulic-powered MR injector eliminates batteries and associated issues.

MULTIHANCE INDICATIONS AND USAGE:
MultiHance is a gadolinium-based contrast agent indicated for use in:

  • Magnetic resonance imaging (MRI) of the central nervous system (CNS) in adults and children over 2 years of age to visualize lesions with abnormal blood-brain b arrier or abnormal vascularity of the brain, spine, and associated tissues and
  • Magnetic resonance angiography (MRA) to evaluate adults with known or suspected renal or aorto-ilio-femoral occlusive vascular disease

IMPORTANT SAFETY INFORMATION

WARNING: NEPHROGENIC SYSTEMIC FIBROSIS

Gadolinium-based contrast agents (GBCAs) increase the risk for NSF among patients with impaired elimination of the drugs. Avoid use of GBCAs in these patients unless the diagnostic information is essential and not available with non-contrasted MRI or other modalities. NSF may result in fatal or debilitating systemic fibrosis affecting the skin, muscle and internal organs.

  • The risk for NSF appears highest among patients with:
    • chronic, severe kidney disease (GFR <30 mL/min/1.73m2), or
    • acute kidney injury.
  • Screen patients for acute kidney injury and other conditions that may reduce renal function. For patients at risk for chronically reduced renal function (e.g. age > 60 years, hypertension or diabetes), estimate the glomerular filtration rate (GFR) through laboratory testing.
  • For patients at highest risk for NSF, do not exceed the recommended MultiHance dose and allow a sufficient period of time for elimination of the drug from the body prior to re-administration [See Warnings and Precautions (5.1)]

Anaphylactic and anaphylactoid reactions have been reported, involving cardiovascular, respiratory, and/or cutaneous manifestations ranging from mild to severe. The possibility of a reaction should always be considered, especially in those patients with a history of a known clinical hypersensitivity or a history of asthma or other allergic disorders.

Please consult full Prescribing Information for MultiHance including boxed WARNING contained within this website.

PROHANCE INDICATIONS AND USAGE
Central Nervous System
ProHance (Gadoteridol) Injection is indicated for use in MRI in adults and children over 2 years of age to visualize lesions with abnormal vascularity in the brain (intracranial lesions), spine and associated tissues.

Extracranial/Extraspinal Tissues
ProHance is indicated for use in MRI in adults to visualize lesions in the head and neck.

IMPORTANT SAFETY INFORMATION

WARNING: NEPHROGENIC SYSTEMIC FIBROSIS

Gadolinium-based contrast agents (GBCAs) increase the risk for NSF among patients with impaired elimination of the drugs. Avoid use of GBCAs in these patients unless the diagnostic information is essential and not available with non-contrasted MRI or other modalities. NSF may result in fatal or debilitating systemic fibrosis affecting the skin, muscle and internal organs.

  • The risk for NSF appears highest among patients with:
    • chronic, severe kidney disease (GFR <30 mL/min/1.73m2), or
    • acute kidney injury.
  • Screen patients for acute kidney injury and other conditions that may reduce renal function. For patients at risk for chronically reduced renal function (e.g. age > 60 years, hypertension or diabetes), estimate the glomerular filtration rate (GFR) through laboratory testing.
  • For patients at highest risk for NSF, do not exceed the recommended ProHance dose and allow a sufficient period of time for elimination of the drug from the body prior to re-administration [See Warnings]

As with all paramagnetic agents, caution should be exercised in patients with deoxygenated sickle erythrocytes and renal insufficiency with or without hepatic impairment. The possibility of a reaction, including serious, life threatening, or fatal, anaphylactic or cardiovascular reactions, or other idiosyncratic reactions, should always be considered, especially in those patients with a history of a known clinical hypersensitivity or a history of asthma or other allergic disorders.

Please consult full Prescribing Information for ProHance including boxed WARNING contained within this website.

You are encouraged to report negative side effects of prescription drugs to the FDA. Visit www.fda.gov/medwatch or call 1-800-FDA-1088.

All trademarks and registered trademarks are the property of their respective owners.

MultiHance®is manufactured for Bracco Diagnostics Inc. by BIPSO GmbH – 78224 Singen (Germany) and by Patheon Italia SpA, Ferentino, Italy.
ProHance®is manufactured for Bracco Diagnostics Inc. by BIPSO GmbH – 78224 Singen (Germany).